Jean Sabile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jean Sabile has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. Silver
Division of Hospital Medicine Oregon Health & Science University, School of Medicine Portland Oregon USA
1 shared publication - Amy Zhang
Stanford University School of Medicine, Palo Alto, California, United States
1 shared publication - Andrew Srisuwananukorn
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA
1 shared publication Anil V. Parwani
1 shared publicationArpita P. Gandhi
1 shared publicationAudrey Tran
School of Medicine, Oregon Health & Science University, Portland, Oregon, USA
1 shared publication
Latest Publications
- 11 August 2026
- Published by Wiley in Journal of Ultrasound in Medicine
Point‐of‐Care Ultrasound Correlates of Pulmonary Capillary Wedge Pressure and Right Atrial Pressure
Objectives: Volume assessment remains a challenging bedside practice that is highly dependent on patient factors, comorbid conditions, physical exam, and point‐of‐care ultrasound (POCUS) techniques. POCUS is increasingly used to assist with diuretic decision‐making for patients with suspected volume overload. While developing evidence suggests that POCUS allows for rapid and safe evaluation of volume status, limited data exist regarding which POCUS assessments correlate best to filling pressure measurements obtained from rightheart catheterization (RHC). Methods: A single‐center observational exploratory study conducted at Oregon Health & Science University investigated POCUS volume assessment in adult patients scheduled to undergo RHC. Multiple POCUS measurements were performed directly prior to RHC in 28 patients to investigate correlations between POCUS and RHC measurements, specifically mean right atrial pressure (mRAP) and pulmonary capillary wedge pressure (PCWP). Results: POCUS measurements that correlated (either positively or negatively) with mRAP as measured by RHC included qualitative RV function assessment and tricuspid annular plane of systolic excursion (TAPSE) (r S = −0.421, p = 0.032, effect size = −0.699–0.047). Left atrial diameter measurement (r P = 0.651, p = S = 0.394, p = 0.050, effect size = 0.053–0.711), E/A ratio (r S = 0.446, p = 0.025, effect size = 0.048–0.708), total B‐line score (r S = 0.407, p = 0.031, effect size = −0.159–0.615), combined LA diameter and mitral valve inflow velocity (r P = 0.383, p = 0.044, effect size = 0.011–0.661), and combined E/e′ and E/A ratio (r P = 0.418, p = 0.027, effect size = 0.053–0.684) all correlated with PCWP. Discussion: Some correlation exists between POCUS measurements and RHC assessment of PCWP and mRAP. Larger prospective studies are needed to fully understand this correlation, particularly in the context of pre/post intervention and specific disease processes.
- 11 August 2026
- Published by Wiley in Journal of Ultrasound in Medicine
Point‐of‐Care Ultrasound Correlates of Pulmonary Capillary Wedge Pressure and Right Atrial Pressure
Objectives: Volume assessment remains a challenging bedside practice that is highly dependent on patient factors, comorbid conditions, physical exam, and point‐of‐care ultrasound (POCUS) techniques. POCUS is increasingly used to assist with diuretic decision‐making for patients with suspected volume overload. While developing evidence suggests that POCUS allows for rapid and safe evaluation of volume status, limited data exist regarding which POCUS assessments correlate best to filling pressure measurements obtained from rightheart catheterization (RHC). Methods: A single‐center observational exploratory study conducted at Oregon Health & Science University investigated POCUS volume assessment in adult patients scheduled to undergo RHC. Multiple POCUS measurements were performed directly prior to RHC in 28 patients to investigate correlations between POCUS and RHC measurements, specifically mean right atrial pressure (mRAP) and pulmonary capillary wedge pressure (PCWP). Results: POCUS measurements that correlated (either positively or negatively) with mRAP as measured by RHC included qualitative RV function assessment and tricuspid annular plane of systolic excursion (TAPSE) (r S = −0.421, p = 0.032, effect size = −0.699–0.047). Left atrial diameter measurement (r P = 0.651, p = S = 0.394, p = 0.050, effect size = 0.053–0.711), E/A ratio (r S = 0.446, p = 0.025, effect size = 0.048–0.708), total B‐line score (r S = 0.407, p = 0.031, effect size = −0.159–0.615), combined LA diameter and mitral valve inflow velocity (r P = 0.383, p = 0.044, effect size = 0.011–0.661), and combined E/e′ and E/A ratio (r P = 0.418, p = 0.027, effect size = 0.053–0.684) all correlated with PCWP. Discussion: Some correlation exists between POCUS measurements and RHC assessment of PCWP and mRAP. Larger prospective studies are needed to fully understand this correlation, particularly in the context of pre/post intervention and specific disease processes.
- 13 March 2026
- Published by S. Karger AG in Acta Haematologica
- p. 1-6
A Complex Case of Anti-e Mimicking Autoantibody Development Leading to Warm Autoimmune Hemolytic Anemia: Case Report
Introduction: Newly diagnosed autoimmune hemolytic anemia (AIHA) develops in 1–3 individuals per 100,000 people per year. Warm autoimmune hemolytic anemia (WAIHA) is the most common type of AIHA, accounting for approximately 70–80% of cases. This report outlines a complex presentation of DAT-negative, anti-e-mimicking autoantibody mediated WAIHA following a transient viral infection in an adult male patient with no prior transfusions. Case Presentation: The 55-year-old male patient presented with several weeks of flu-like symptoms followed by jaundice, dyspnea, and progressive fatigue. Initial laboratory workup revealed hemolytic anemia, and subsequent serologic testing identified a warm autoantibody with anti-C specificity, but was ultimately consistent with an anti-e mediated WAIHA. Conclusion: This report highlights a complex case of a patient with an autoantibody mimicking anti-e associated WAIHA and the challenge of identifying suitable transfusion options.
- 13 March 2026
- Published by S. Karger AG in Acta Haematologica
- p. 1-6
A Complex Case of Anti-e Mimicking Autoantibody Development Leading to Warm Autoimmune Hemolytic Anemia: Case Report
Introduction: Newly diagnosed autoimmune hemolytic anemia (AIHA) develops in 1–3 individuals per 100,000 people per year. Warm autoimmune hemolytic anemia (WAIHA) is the most common type of AIHA, accounting for approximately 70–80% of cases. This report outlines a complex presentation of DAT-negative, anti-e-mimicking autoantibody mediated WAIHA following a transient viral infection in an adult male patient with no prior transfusions. Case Presentation: The 55-year-old male patient presented with several weeks of flu-like symptoms followed by jaundice, dyspnea, and progressive fatigue. Initial laboratory workup revealed hemolytic anemia, and subsequent serologic testing identified a warm autoantibody with anti-C specificity, but was ultimately consistent with an anti-e mediated WAIHA. Conclusion: This report highlights a complex case of a patient with an autoantibody mimicking anti-e associated WAIHA and the challenge of identifying suitable transfusion options.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 8549290
Polycythemia Vera Transforming to Pure Erythroid Leukemia: A Diagnostic Mimic of Thrombotic Microangiopathy With High‐Risk TP53 Biology
Leukemic transformation of polycythemia vera (PV) to acute myeloid leukemia (AML) with a predominantly erythroid blast population is rare and carries a poor prognosis, particularly when driven by a TP53 mutation. We report a 55‐year‐old man with JAK2 V617F‐positive PV, previously noted on surveillance biopsy to harbor a TP53 mutation and Grade 2 marrow fibrosis, who presented three years later with pancytopenia, schistocytosis, hyperferritinemia, hypofibrinogenemia, and altered mental status. The initial clinical presentation raised concern for thrombotic thrombocytopenic purpura (TTP), while the presence of rare circulating blasts and coagulopathy also prompted consideration of acute promyelocytic leukemia (APML). Empiric plasma exchange, corticosteroids, and all‐trans retinoic acid were initiated. ADAMTS13 activity and PML‐RARA FISH subsequently returned negative. The patient deteriorated with multiorgan failure and expired before leukemia‐directed therapy could be initiated. Postmortem bone marrow results demonstrated greater than 90% erythroid blasts with TP53 protein overexpression, a TP53 p.C238Y mutation (VAF 66%), and a triploid karyotype with 7p and 19p abnormalities, consistent with pure erythroid leukemia (PEL) arising from an antecedent myeloproliferative neoplasm. This case highlights the diagnostic challenges posed by overlapping clinical features of TTP and APML, including limitations in immunophenotypic assignment of the erythroid lineage. Importantly, it provides a longitudinally documented example of a TP53 mutation detected three years before overt transformation and describes a previously unreported presentation mimicking both TTP and APML.
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 8549290
Open AccessPolycythemia Vera Transforming to Pure Erythroid Leukemia: A Diagnostic Mimic of Thrombotic Microangiopathy With High‐Risk TP53 Biology
Leukemic transformation of polycythemia vera (PV) to acute myeloid leukemia (AML) with a predominantly erythroid blast population is rare and carries a poor prognosis, particularly when driven by a TP53 mutation. We report a 55‐year‐old man with JAK2 V617F‐positive PV, previously noted on surveillance biopsy to harbor a TP53 mutation and Grade 2 marrow fibrosis, who presented three years later with pancytopenia, schistocytosis, hyperferritinemia, hypofibrinogenemia, and altered mental status. The initial clinical presentation raised concern for thrombotic thrombocytopenic purpura (TTP), while the presence of rare circulating blasts and coagulopathy also prompted consideration of acute promyelocytic leukemia (APML). Empiric plasma exchange, corticosteroids, and all‐trans retinoic acid were initiated. ADAMTS13 activity and PML‐RARA FISH subsequently returned negative. The patient deteriorated with multiorgan failure and expired before leukemia‐directed therapy could be initiated. Postmortem bone marrow results demonstrated greater than 90% erythroid blasts with TP53 protein overexpression, a TP53 p.C238Y mutation (VAF 66%), and a triploid karyotype with 7p and 19p abnormalities, consistent with pure erythroid leukemia (PEL) arising from an antecedent myeloproliferative neoplasm. This case highlights the diagnostic challenges posed by overlapping clinical features of TTP and APML, including limitations in immunophenotypic assignment of the erythroid lineage. Importantly, it provides a longitudinally documented example of a TP53 mutation detected three years before overt transformation and describes a previously unreported presentation mimicking both TTP and APML.
- 24 July 2025
- Published by S. Karger AG in Acta Haematologica
- Vol. 148 (5) , 583-599
Toward Clinically Actionable Machine Learning and Artificial Intelligence Algorithms in Acute Leukemia: A Systematic Narrative Review
Introduction: Acute myeloid leukemia (AML) is a heterogenous hematologic malignancy that maintains high relapse rates and poor survival despite ongoing treatment advances. There is critically unmet need for consistently providing long-term survival with minimal treatment toxicity for AML patients. Advances in artificial intelligence/machine learning (AI/ML) offer new approaches to addressing clinical challenges in AML. Methods: In this systematic narrative review, 426 publications focusing on the intersection of AML and AI/ML between January 1, 2010, and July 30, 2024, are reviewed. Results: The evolution of AI/ML tools over time is described from a clinically relevant perspective with a distinction between early epochs of AI/ML versus more contemporary algorithms, such as generative adversarial networks and transformer-based algorithms. This review highlights the utilization of contemporary AI/ML algorithms via addressing diagnostic challenges, molecular risk stratification problems, and clinical outcome prediction in the context of AML. Conclusion: Overall, AI/ML represents a promising new frontier in approaching clinical problems in AML, though there are still opportunities for utilization, particularly in the setting of allogeneic stem cell transplantation.
- 24 July 2025
- Published by S. Karger AG in Acta Haematologica
- Vol. 148 (5) , 583-599
Toward Clinically Actionable Machine Learning and Artificial Intelligence Algorithms in Acute Leukemia: A Systematic Narrative Review
Introduction: Acute myeloid leukemia (AML) is a heterogenous hematologic malignancy that maintains high relapse rates and poor survival despite ongoing treatment advances. There is critically unmet need for consistently providing long-term survival with minimal treatment toxicity for AML patients. Advances in artificial intelligence/machine learning (AI/ML) offer new approaches to addressing clinical challenges in AML. Methods: In this systematic narrative review, 426 publications focusing on the intersection of AML and AI/ML between January 1, 2010, and July 30, 2024, are reviewed. Results: The evolution of AI/ML tools over time is described from a clinically relevant perspective with a distinction between early epochs of AI/ML versus more contemporary algorithms, such as generative adversarial networks and transformer-based algorithms. This review highlights the utilization of contemporary AI/ML algorithms via addressing diagnostic challenges, molecular risk stratification problems, and clinical outcome prediction in the context of AML. Conclusion: Overall, AI/ML represents a promising new frontier in approaching clinical problems in AML, though there are still opportunities for utilization, particularly in the setting of allogeneic stem cell transplantation.
- Open Access
Can Electronic care planning using AI Summarization Yield equal Documentation Quality? (EASY eDocQ)
Importance Data, information and knowledge in health care has expanded exponentially over the last 50 years, leading to significant challenges with information overload and complex, fragmented care plans. Generative AI has the potential to facilitate summarization and integration of knowledge and wisdom to through rapid integration of data and information to enable efficient care planning. Objective Our objective was to understand the value of AI generated summarization through short synopses at the care transition from hospital to first outpatient visit. Design Using a de-identified data set of recently hospitalized patients with multiple chronic illnesses, we used the data-information-knowledge-wisdom framework to train clinicians and an open-source generative AI Large Language Model system to produce summarized patient assessments after hospitalizations. Both sets of synopses were judged blinded in random order by clinician judges. Participants De-identified patients had multiple chronic conditions and a recent hospitalization. Raters were physicians at various levels of training. Main outcome Accuracy, succinctness, synthesis and usefulness of synopses using a standardized scale with scores > 80% indicating success. Results AI and clinicians summarized 80 patients with 10% overlap. In blinded trials, AI synopses were rated as useful 75% of the time versus 76% for human generated ones. AI had lower succinctness ratings for the Data synopsis task (55-67%) versus human (84-86%). For accuracy and synthesis, AI had near equal or better scores in other domains (AI: 72%-79%, humans: 68%-84%), with best scores from AI in Wisdom. Interrater agreement was moderate, indicating different preferences for synopsis content, and did not vary between AI and human-created synopses. Discussion AI-created synopses that were nearly equivalent to human-created ones; they were slightly longer and did not always synthesize individual data elements compared to humans. Given their rapid introduction into clinical care, our framework and protocol for evaluation of these tools provides strong benchmarking capabilities for developers and implementers. Question Can a Generative AI Large Language Model be trained to generate accurate and useful patient synopses through chart summarization for use in outpatient settings after hospital discharge? Findings Using a Data-Information-Knowledge-Wisdom framework, clinicians and an open-source AI system were trained to summarize charts; these synopses were rated blindly using a standardized index. Synopses from the AI were rated as useful 75% of the time versus 76% for human generated ones, AI synopses scored highest in Wisdom for accuracy and synthesis. Interrater agreement was moderate but did not vary between AI and human. Meaning This study provides a concrete, replicable protocol for benchmarking LLM summarization outputs and demonstrates general equivalence to human-created synopses for outpatient use after care transitions.
Open AccessCan Electronic care planning using AI Summarization Yield equal Documentation Quality? (EASY eDocQ)
Importance Data, information and knowledge in health care has expanded exponentially over the last 50 years, leading to significant challenges with information overload and complex, fragmented care plans. Generative AI has the potential to facilitate summarization and integration of knowledge and wisdom to through rapid integration of data and information to enable efficient care planning. Objective Our objective was to understand the value of AI generated summarization through short synopses at the care transition from hospital to first outpatient visit. Design Using a de-identified data set of recently hospitalized patients with multiple chronic illnesses, we used the data-information-knowledge-wisdom framework to train clinicians and an open-source generative AI Large Language Model system to produce summarized patient assessments after hospitalizations. Both sets of synopses were judged blinded in random order by clinician judges. Participants De-identified patients had multiple chronic conditions and a recent hospitalization. Raters were physicians at various levels of training. Main outcome Accuracy, succinctness, synthesis and usefulness of synopses using a standardized scale with scores > 80% indicating success. Results AI and clinicians summarized 80 patients with 10% overlap. In blinded trials, AI synopses were rated as useful 75% of the time versus 76% for human generated ones. AI had lower succinctness ratings for the Data synopsis task (55-67%) versus human (84-86%). For accuracy and synthesis, AI had near equal or better scores in other domains (AI: 72%-79%, humans: 68%-84%), with best scores from AI in Wisdom. Interrater agreement was moderate, indicating different preferences for synopsis content, and did not vary between AI and human-created synopses. Discussion AI-created synopses that were nearly equivalent to human-created ones; they were slightly longer and did not always synthesize individual data elements compared to humans. Given their rapid introduction into clinical care, our framework and protocol for evaluation of these tools provides strong benchmarking capabilities for developers and implementers. Question Can a Generative AI Large Language Model be trained to generate accurate and useful patient synopses through chart summarization for use in outpatient settings after hospital discharge? Findings Using a Data-Information-Knowledge-Wisdom framework, clinicians and an open-source AI system were trained to summarize charts; these synopses were rated blindly using a standardized index. Synopses from the AI were rated as useful 75% of the time versus 76% for human generated ones, AI synopses scored highest in Wisdom for accuracy and synthesis. Interrater agreement was moderate but did not vary between AI and human. Meaning This study provides a concrete, replicable protocol for benchmarking LLM summarization outputs and demonstrates general equivalence to human-created synopses for outpatient use after care transitions.
- 30 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 678-686
Estrogen‐based hormonal therapy and the risk of thrombosis in COVID‐19 patients
Objective: Estrogen‐containing contraceptives and hormone replacement therapy are used commonly, however, the risks of venous and arterial thrombosis imparted by such medications during COVID‐19 infection or other similar viral infections remain undescribed.Methods: To assess the risk of venous and arterial thrombosis in patients receiving oral estrogen‐containing therapy (ECT) with COVID‐19 as compared to those receiving non‐estrogen‐based hormonal therapy, we conducted a multicenter cohort study of 991 patients with confirmed COVID‐19 infection, 466 receiving estrogen‐containing hormonal therapy, and 525 receiving progestin‐only or topical therapy.Results: The use of estrogen‐containing therapy was found to significantly increase the risk of venous thromboembolism (VTE) following COVID‐19 diagnosis after controlling for age (HR 5.46 [95% CI 1.12–26.7, p = .036]). This risk was highest in patients over age 50, with 8.6% of patients receiving estrogen‐containing therapy diagnosed with VTE compared to 0.9% of those receiving non‐estrogen‐based therapies (p = .026). The risk of arterial thrombosis was not significantly associated with oral estrogen use.Conclusions: These results suggest that estrogen‐containing therapy is associated with a significantly increased risk of VTE in COVID‐19 patients, especially in older individuals. These findings may guide provider counseling and management of patients with COVID‐19 on estrogen‐containing therapy.
- 30 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (5) , 678-686
Estrogen‐based hormonal therapy and the risk of thrombosis in COVID‐19 patients
Objective: Estrogen‐containing contraceptives and hormone replacement therapy are used commonly, however, the risks of venous and arterial thrombosis imparted by such medications during COVID‐19 infection or other similar viral infections remain undescribed.Methods: To assess the risk of venous and arterial thrombosis in patients receiving oral estrogen‐containing therapy (ECT) with COVID‐19 as compared to those receiving non‐estrogen‐based hormonal therapy, we conducted a multicenter cohort study of 991 patients with confirmed COVID‐19 infection, 466 receiving estrogen‐containing hormonal therapy, and 525 receiving progestin‐only or topical therapy.Results: The use of estrogen‐containing therapy was found to significantly increase the risk of venous thromboembolism (VTE) following COVID‐19 diagnosis after controlling for age (HR 5.46 [95% CI 1.12–26.7, p = .036]). This risk was highest in patients over age 50, with 8.6% of patients receiving estrogen‐containing therapy diagnosed with VTE compared to 0.9% of those receiving non‐estrogen‐based therapies (p = .026). The risk of arterial thrombosis was not significantly associated with oral estrogen use.Conclusions: These results suggest that estrogen‐containing therapy is associated with a significantly increased risk of VTE in COVID‐19 patients, especially in older individuals. These findings may guide provider counseling and management of patients with COVID‐19 on estrogen‐containing therapy.
- Open Access
- 6 June 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (14) , 3395-3402
Next-generation sequencing–based MRD in adults with ALL undergoing hematopoietic cell transplantation
Measurable residual disease (MRD) is an adverse prognostic factor in adult patients with acute lymphoblastic leukemia (ALL) undergoing hematopoietic cell transplant (HCT). Next-generation sequencing (NGS) can detect MRD with a sensitivity of 10–6, but the prognostic value of NGS-based MRD in adult patients with ALL undergoing HCT remains minimally studied. To evaluate the prognostic value of NGS-based MRD in adult patients with ALL undergoing HCT, patients aged ≥18 years with ALL who underwent allogeneic HCT at Stanford University or Oregon Health & Science University between January 2014 and April 2021 and were evaluated for MRD using the NGS-based clonoSEQ assay were included in this study. MRD was assessed before HCT (MRDpre) and up to 1 year after HCT (MRDpost). Patients were followed up for leukemia relapse and survival for up to 2 years after HCT. In total, 158 patients had a trackable clonotype for MRD monitoring. The cumulative incidence of relapse was increased at all levels of MRDpre, including in patients who had low MRDpre of <10–4 (hazard ratio [HR], 3.56; 95% confidence interval [95% CI], 1.39-9.15). In multivariable analysis, MRDpre level remained significantly prognostic; however, detectable MRDpost was the strongest predictor of relapse (HR, 4.60; 95% CI, 3.01-7.02). In exploratory analyses limited to patients with B-cell ALL, the detection of post-HCT immunoglobulin H (IgH) MRD clonotypes, rather than non-IgH MRD clonotypes, was associated with relapse. In this analysis across 2 large transplant centers, we found that the detection of MRD by NGS at a level of 10–6 offers significant prognostic value in adults with ALL undergoing HCT.
- 6 June 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (14) , 3395-3402
Open AccessNext-generation sequencing–based MRD in adults with ALL undergoing hematopoietic cell transplantation
Measurable residual disease (MRD) is an adverse prognostic factor in adult patients with acute lymphoblastic leukemia (ALL) undergoing hematopoietic cell transplant (HCT). Next-generation sequencing (NGS) can detect MRD with a sensitivity of 10–6, but the prognostic value of NGS-based MRD in adult patients with ALL undergoing HCT remains minimally studied. To evaluate the prognostic value of NGS-based MRD in adult patients with ALL undergoing HCT, patients aged ≥18 years with ALL who underwent allogeneic HCT at Stanford University or Oregon Health & Science University between January 2014 and April 2021 and were evaluated for MRD using the NGS-based clonoSEQ assay were included in this study. MRD was assessed before HCT (MRDpre) and up to 1 year after HCT (MRDpost). Patients were followed up for leukemia relapse and survival for up to 2 years after HCT. In total, 158 patients had a trackable clonotype for MRD monitoring. The cumulative incidence of relapse was increased at all levels of MRDpre, including in patients who had low MRDpre of <10–4 (hazard ratio [HR], 3.56; 95% confidence interval [95% CI], 1.39-9.15). In multivariable analysis, MRDpre level remained significantly prognostic; however, detectable MRDpost was the strongest predictor of relapse (HR, 4.60; 95% CI, 3.01-7.02). In exploratory analyses limited to patients with B-cell ALL, the detection of post-HCT immunoglobulin H (IgH) MRD clonotypes, rather than non-IgH MRD clonotypes, was associated with relapse. In this analysis across 2 large transplant centers, we found that the detection of MRD by NGS at a level of 10–6 offers significant prognostic value in adults with ALL undergoing HCT.
- Open Access
- 25 April 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15 (4) , e249683
Complete occlusion of the left pulmonary artery and paradoxical cerebral embolus from tricuspid valve endocarditis
- 25 April 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15 (4) , e249683
Open AccessComplete occlusion of the left pulmonary artery and paradoxical cerebral embolus from tricuspid valve endocarditis
- Open Access
- 12 May 2021
- Published by Hindawi Limited in Case Reports in Oncological Medicine
- Vol. 2021, 1-5
Posterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma
Background. The role of immunotherapy continues to evolve across both solid and hematologic malignancies. However, while use of immunotherapy has increased via the advent of checkpoint inhibition, chimeric antigen receptors, and vaccines against malignant cells, there remains uncertainty regarding the recognition and management of delayed immune-related reactions and post treatment immune-related sensitivity to subsequent medications, such as BRAF/MEK kinase inhibitors. Furthermore, it is unclear how immunotherapy may alter the adverse effect profile and efficacy of subsequent lines of treatment. Case Presentation. Discussed is a patient with stage IV metastatic melanoma who failed first-line treatment with a combination of nivolumab and ipilimumab. He was then treated with BRAF/MEK kinase inhibition via Encorafenib and Binimetinib. Shortly thereafter, the patient developed posterior reversible encephalopathy syndrome (PRES) and a generalized pruritic rash that was biopsied with consideration toward drug reaction versus drug-induced hypersensitivity syndrome (DIHS), formerly called drug reaction with eosinophilia and systemic symptoms (DRESS). The BRAF/MEK combination was held and steroid taper initiated with continued response even beyond conclusion of the steroid taper. Discussion and Conclusions. This case highlights the diagnostic challenge presented by PRES and DIHS in the setting of immunotherapy and BRAF/MEK kinase inhibition for malignant melanoma. The clinical rationale for reinitiating therapy following severe immune reactions subsequent to immunotherapy in the setting of relapsed/refractory metastatic melanoma is discussed. Additionally, the durable response our patient experienced throughout the drug hold period and steroid taper and its clinical potential etiologies and applications are reviewed. As checkpoint inhibition and tyrosine-kinase inhibitors have become cornerstones of cancer therapy, larger studies and long-term observations are needed to investigate the risks and benefits across different sequences of therapy.
- 12 May 2021
- Published by Hindawi Limited in Case Reports in Oncological Medicine
- Vol. 2021, 1-5
Open AccessPosterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma
Background. The role of immunotherapy continues to evolve across both solid and hematologic malignancies. However, while use of immunotherapy has increased via the advent of checkpoint inhibition, chimeric antigen receptors, and vaccines against malignant cells, there remains uncertainty regarding the recognition and management of delayed immune-related reactions and post treatment immune-related sensitivity to subsequent medications, such as BRAF/MEK kinase inhibitors. Furthermore, it is unclear how immunotherapy may alter the adverse effect profile and efficacy of subsequent lines of treatment. Case Presentation. Discussed is a patient with stage IV metastatic melanoma who failed first-line treatment with a combination of nivolumab and ipilimumab. He was then treated with BRAF/MEK kinase inhibition via Encorafenib and Binimetinib. Shortly thereafter, the patient developed posterior reversible encephalopathy syndrome (PRES) and a generalized pruritic rash that was biopsied with consideration toward drug reaction versus drug-induced hypersensitivity syndrome (DIHS), formerly called drug reaction with eosinophilia and systemic symptoms (DRESS). The BRAF/MEK combination was held and steroid taper initiated with continued response even beyond conclusion of the steroid taper. Discussion and Conclusions. This case highlights the diagnostic challenge presented by PRES and DIHS in the setting of immunotherapy and BRAF/MEK kinase inhibition for malignant melanoma. The clinical rationale for reinitiating therapy following severe immune reactions subsequent to immunotherapy in the setting of relapsed/refractory metastatic melanoma is discussed. Additionally, the durable response our patient experienced throughout the drug hold period and steroid taper and its clinical potential etiologies and applications are reviewed. As checkpoint inhibition and tyrosine-kinase inhibitors have become cornerstones of cancer therapy, larger studies and long-term observations are needed to investigate the risks and benefits across different sequences of therapy.
- 1 February 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (2) , 118-120
Primary Bone Marrow Epithelioid Hemangioendothelioma Treated With Gemcitabine and Docetaxel
- 1 February 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (2) , 118-120
Primary Bone Marrow Epithelioid Hemangioendothelioma Treated With Gemcitabine and Docetaxel